Poor
Not Aligned
Patient Risk:
Moderate
Summary
Most statements are not supported by the provided FDA label excerpts; several safety/efficacy explanations (e.g., “gradual loss of potency from age,” general resistance causality, and specific counseling details) are not explicitly addressed in the supplied label text and therefore cannot be confirmed.
Category Scores
Accurate Statements
If symptoms don’t improve as expected, worsen quickly, or keep returning more severely, contacting a clinician is recommended to assess for resistant virus, wrong diagnosis, or dosing/timing problem and to consider alternatives.
Partially consistent with label counseling/timing concepts (treatment should be initiated as soon as possible after diagnosis for herpes zoster; for genital herpes there is patient counseling that acyclovir is not a cure). However, the label excerpt does not explicitly support the specific “worsen quickly/keep returning more severely” trigger or the enumerated assessment list for treatment failure.
Unsupported Statements
There is no general rule that acyclovir becomes less effective just because time passes.
No provided label excerpt addresses loss of effectiveness over time beyond expiration/storage or resistance; the statement is not supported by the supplied label text.
Acyclovir effectiveness depends mainly on whether the product is still valid/usable and whether it is being used correctly, not on a gradual loss of potency from "age" in the body.
The provided label excerpts do not state that effectiveness depends mainly on product validity/use vs “gradual loss of potency from age in the body.”
Most "effectiveness decrease" issues with acyclovir come from product stability and expiration.
No provided label excerpt discusses product stability/expiration as the main cause of reduced effectiveness.
If acyclovir is past its expiration date or stored improperly (too hot, exposed to moisture, or left in a hot car), the drug may degrade and become less effective.
No storage/handling or expiration-related statements are included in the provided label excerpts.
For herpes viruses, effectiveness can drop in some people due to viral resistance rather than drug aging.
The provided label excerpts do not mention viral resistance affecting response.
Prolonged or repeated acyclovir use can increase the chance of viral resistance.
Not supported in the supplied label excerpts.
Viral resistance is more likely in people with weakened immune systems.
Not supported in the supplied label excerpts (no resistance statements provided).
With viral resistance, the virus may no longer respond to acyclovir as well.
Not supported in the supplied label excerpts.
Clinicians may switch to a different antiviral strategy when resistance occurs.
Not supported in the supplied label excerpts.
A lack of response to acyclovir can be due to incorrect diagnosis.
Not supported by the supplied label excerpts.
A lack of response to acyclovir can be due to taking the wrong dose or timing.
While the label excerpts include specific initiation timing for zoster and chickenpox, they do not explicitly support this general statement about treatment failure causes.
A lack of response to acyclovir can be due to not starting early enough for the specific infection.
The label includes initiation-as-soon-as-possible statements for herpes zoster and time-to-initiation data for chickenpox, but it does not frame this as a general cause of “lack of response” for all infections; still, partially related, but the statement is broader than supported.
A lack of response to acyclovir can be due to adherence issues.
Not supported in the supplied label excerpts.
Resistance is only one possible explanation for treatment failure.
Resistance is not addressed in the provided label excerpts; therefore this cannot be supported.
Resistance is more likely with repeated episodes or immunocompromise.
Not supported in the supplied label excerpts.
Oral tablets, topical creams, and intravenous formulations can have different stability requirements and real-world reliability.
Not supported in the provided label excerpts; topical creams are not addressed for acyclovir in the supplied sections.
Main "over time" concerns for acyclovir relate to expiration/storage and to whether the virus has developed resistance.
Expiration/storage and viral resistance are not discussed in the provided label excerpts.
Contradictions
Low
AI Statement
Prolonged or repeated acyclovir use can increase the chance of viral resistance.
Label Reference
Not found in the provided label excerpts (no resistance statements provided).
Important Omissions
For herpes zoster, the label specifies there are no data on treatment initiated more than 72 hours after onset and advises initiating as soon as possible after diagnosis of herpes zoster.
Importance:
Moderate
The label includes specific dosage regimens by indication and requires renal dose modification and possible post-hemodialysis additional dosing; the response provides no dosing information.
Importance:
Moderate
Label warnings include renal failure (sometimes resulting in death) and TTP/HUS occurring in immunocompromised patients; the response does not include these safety warnings.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response introduces multiple claims about reduced effectiveness causes (expiration/storage, viral resistance, adherence, resistance likelihood) without support from the provided label excerpts. While it does recommend clinician contact if symptoms do not improve, several missing/omitted label safety and dosing/renal considerations increase uncertainty.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple assertions are not supported by the provided FDA label excerpts (especially viral resistance and expiration/storage explanations), and key on-label points (specific dosing/timing and renal safety warnings) are omitted.
Suggested Improvement
Restrict claims to what is present in the provided label excerpts (e.g., initiation timing for zoster and chickenpox, renal impairment dose adjustment, and listed safety warnings), and avoid unsupported explanations about viral resistance and expiration/storage unless those sections are provided in the label text.